Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;79(10):1186-9.
doi: 10.1136/jnnp.2007.131334.

TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia

C C Weihl  1 , P Temiz, S E Miller, G Watts, C Smith, M Forman, P I Hanson, V Kimonis, A Pestronk
Affiliations

TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia

C C Weihl et al. J Neurol Neurosurg Psychiatry. 2008 Oct.

Abstract

TAR DNA binding protein-43 (TDP-43) is found in ubiquitinated inclusions (UBIs) in some frontotemporal dementias (FTD-U). One form of FTD-U, due to mutations in the valosin containing protein (VCP) gene, occurs with an inclusion body myopathy (IBMPFD). Since IBMPFD brain has TDP-43 in UBIs, we looked for TDP-43 inclusions in IBMPFD muscle. In normal muscle, TDP-43 is present in nuclei. In IBMPFD muscle, TDP-43 is additionally present as large inclusions within UBIs in muscle cytoplasm. TDP-43 inclusions were also found in 78% of sporadic inclusion body myositis (sIBM) muscles. In IBMPFD and sIBM muscle, TDP-43 migrated with an additional band on immunoblot similar to that reported in FTD-U brains. This study adds sIBM and hereditary inclusion body myopathies to the growing list of TDP-43 positive inclusion diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A) Normal muscle immunostained with anti-TDP-43 antibody and counterstained with DAPI to allow visualization of nuclei. Figure is overlay of anti-TDP-43 and DAPI images. Arrows denote blue nuclei with TDP-43 (red dots) in scattered myonuclei. B) IBMPFD patient tissue immunostained with anti-TDP-43 (brown) and counterstained with Congo red to allow visualization of nuclei and myofibers. Arrows denote large inclusions, some of which are peripherally based. C) Overlay of anti-TDP-43 (orange) and DAPI (blue) of IBMPFD patient tissue. Note that large peripheral inclusions do not localize within nuclei (arrows). D) IBMPFD patient tissue co-immunostained with anti-TDP-43 (red) and FK2 (green). Note that TDP-43 inclusions co-localize with FK2 (ubiquitinated proteins) (arrows). E) IBMPFD patient tissue co-immunostained with anti-TDP-43 (red) and SMI-31, an antibody against phosphorylated tau epitopes (green). Note that some TDP-43 inclusions co-localize with SMI31 (closed arrows) and others do not (open arrows).
Figure 2
Figure 2
A) sIBM patient tissue immunostained with anti-TDP-43 (brown) and counterstained with Congo red to allow visualization of nuclei and myofibers. TDP-43 inclusions are small, in angular fibers and occasionally surround rimmed vacuoles. B) Overlay of sIBM patient biopsy immunostained with TDP-43 (red) and FK2, for ubiquitinated proteins (green). TDP-43 inclusions do not co-localize with ubiquitin. C) sIBM patient tissue co-immunostained with anti-TDP-43 (red) and anti-CD8 (green at focal sites of inflammation). Note the co-localization of TDP-43 and CD8. This is in contrast to an adjacent fiber (arrow) with sarcoplasmic TDP-43 inclusions that does not co-localize with CD8. D) Muscle tissue from sIBM, IBMPFD and normal patient biopsies were homogenized and separated by SDS-PAGE. The subsequent gel was transferred to nitrocellulose and immunoblotted with an antibody to TDP-43. Normal tissue has a discrete band at 43kDa consistent with TDP-43, while sIBM and IBMPFD have a more prominent band and also a higher migrating band. Myosin is show as a loading control. All tissues are from flash frozen biopsies except the lane noted with an * which is from autopsy muscle. All bands are from the same autoradiograph and moved for presentation purposes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3. - PubMed
    1. Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, et al. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol. 2006;65(6):571–81. - PubMed
    1. Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007;66(2):152–7. - PubMed
    1. Hubbers CU, Clemen CS, Kesper K, Boddrich A, Hofmann A, Kamarainen O, et al. Pathological consequences of VCP mutations on human striated muscle. Brain. 2006 - PubMed
    1. Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology. 2006;66(2 Suppl 1):S39–48. - PubMed

MeSH terms